about
Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosisStructure-based optimization of potent PDK1 inhibitorsNMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastasesDiscovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitorsDiscovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer TherapyDesign and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSARA novel multiple-stage antimalarial agent that inhibits protein synthesisPharmacophore features distributions in different classes of compounds.Prediction of Drug Penetration in Tuberculosis LesionsDNA-binding mechanism of the Escherichia coli Ada O(6)-alkylguanine-DNA alkyltransferase.Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase.The structure-based design and synthesis of selective inhibitors of Trypanosoma cruzi dihydrofolate reductase.2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase.Dihydrofolate reductase: a potential drug target in trypanosomes and leishmania.Exhaustive sampling of the fragment space associated to a molecule leading to the generation of conserved fragments.Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA.Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisPharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the FutureClinical and veterinary trypanocidal benzoxaboroles target CPSF3Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovaniLysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosisPreclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionIdentification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase.Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrBOn-Chip Screening of a Glycomimetic Library with C-Type Lectins Reveals Structural Features Responsible for Preferential Binding of Dectin-2 over DC-SIGN/R and LangerinA platform for target prediction of phenotypic screening hit moleculesThe Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani
P50
Q27644255-644E1001-5E9E-426E-8229-AB6C46CBC9F5Q27663311-069F6067-368D-4B2F-AC97-50DD63391B3EQ27684628-8DA5EFA8-625C-481F-93B1-D9A24414582BQ27686961-B9B5E3A7-1B43-4135-AFB0-CFC0371C54FCQ27690826-F1150918-547F-4623-A6FD-2CABD01F294CQ27701674-4D7D39B8-2E62-46F3-98D9-6454E175FCAAQ28373848-AE794AA1-8E7B-46EA-8951-D3DB75B61235Q30044020-1B020DFF-908D-416F-95C5-3364B1C9727DQ33193136-18DA10E7-AA76-4523-A0FC-EA1503CAD265Q37265786-73A97701-5369-4B51-9AF4-A80ED99EBC99Q39584541-3ABCA12F-D921-4AA4-9AA4-8A0BA43BBED6Q40792788-EBC9C783-19BE-4DA5-BCC8-BC2C13F2F467Q40949976-CB1C0EE7-103C-46F5-BD36-ED063CC0C8D5Q44615883-5F963657-BA46-458B-B5A6-A8ADD71E5511Q47624951-568D3B1E-0CC4-4F31-AA49-230D5E868D66Q47632897-5C74D509-CD57-4B7A-84B4-8C542D79C11EQ49330155-0863B0CA-21AA-492E-87DE-96401F8B67C3Q51711730-2BF9237D-55B9-4E2F-974F-5CA3A8F92479Q56565594-539A98D2-1BF1-463A-8026-6E1B94946AE0Q57158690-4F4970FC-AF1A-42BC-8A68-FBB93EC20996Q58842203-7B200CAC-7C9F-4312-8810-C56255DF11ACQ58867156-8265C555-8810-4504-9B12-8E83D07227B2Q62997191-FFBBB829-E951-4FB3-82A5-B09A8AD4B42AQ64068249-080F743E-5BDC-4268-A16A-8715216078A7Q88131729-96D804DB-DDAE-4BF2-B90E-2F2B89A4FBB8Q89257069-9AFC7C0A-B041-49A8-BA1F-5F40D1682165Q89429231-0C5A0F0F-EB68-40EB-9E8C-7ABEB2A15710Q91970417-142E7FFC-33EA-426E-8829-F1D85442F2DBQ92847998-E0315A57-4229-4461-A62D-A6FC754E6C5E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fabio Zuccotto
@ast
Fabio Zuccotto
@en
Fabio Zuccotto
@es
Fabio Zuccotto
@nl
Fabio Zuccotto
@sl
type
label
Fabio Zuccotto
@ast
Fabio Zuccotto
@en
Fabio Zuccotto
@es
Fabio Zuccotto
@nl
Fabio Zuccotto
@sl
prefLabel
Fabio Zuccotto
@ast
Fabio Zuccotto
@en
Fabio Zuccotto
@es
Fabio Zuccotto
@nl
Fabio Zuccotto
@sl
P106
P1153
6602263907
P21
P31
P496
0000-0002-3888-7423